Your browser doesn't support javascript.
loading
Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma.
Song, Yu-Qin; Zhang, Hui-Lai; Huang, Hui-Qiang; Zhang, Qing-Yuan; Jing, Hong-Mei; Wang, Chao; Wu, Chun; Li, Dong-Hang; Dai, Yu; Humphrey, Kathryn; Zhu, Jun.
Afiliação
  • Song YQ; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing.
  • Zhang HL; Tianjin Medical University Cancer Institute and Hospital, Tianjin.
  • Huang HQ; Sun Yatsen University Cancer Center, Guangzhou.
  • Zhang QY; Harbin Medical University Cancer Hospital, Harbin.
  • Jing HM; Peking University Third Hospital, Beijing.
  • Wang C; Roche (China) Holding Ltd., Shanghai.
  • Wu C; Roche (China) Holding Ltd., Shanghai.
  • Li DH; Roche (China) Holding Ltd., Shanghai.
  • Dai Y; Roche RD Center (China) Ltd., Shanghai.
  • Humphrey K; Roche Products Ltd., Welwyn Garden City, UK.
  • Zhu J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing. zhujun@csco.org.cn.
Haematologica ; 109(4): 1269-1273, 2024 Apr 01.
Article em En | MEDLINE | ID: mdl-37855035
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Linfoma Difuso de Grandes Células B / Anticorpos Biespecíficos Limite: Humans País como assunto: Asia Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma não Hodgkin / Linfoma Difuso de Grandes Células B / Anticorpos Biespecíficos Limite: Humans País como assunto: Asia Idioma: En Ano de publicação: 2024 Tipo de documento: Article